Japanese PM, Pfizer CEO discuss delivery of additional vaccine doses in 2021 to Japan

Coronavirus chronicle

Reuters
18 April, 2021, 10:55 am
Last modified: 18 April, 2021, 10:56 am
Japan's Nikkei newspaper reported earlier that Suga asked Pfizer to provide more vaccine doses

Japanese Prime Minister Yoshihide Suga asked US drugmaker Pfizer Inc on Saturday to provide additional supplies of Covid-19 vaccine to Japan this year, Nikkei reported.

Pfizer confirmed in an email that Pfizer CEO Albert Bourla met with Suga virtually to discuss vaccine supply on the last day of Suga's three-day visit to Washington. The Pfizer/BioNTech vaccine is the only one approved in Japan.

Japan's Nikkei newspaper reported earlier that Suga asked Pfizer to provide more vaccine doses.

Inoculations of Japan's sizable elderly population began on Monday, but some experts cautioned that the general population may not have access to vaccination until late summer or even winter because of constrained supplies.

Japan was among the last major economies to begin Covid-19 inoculations when it started in mid-February, after domestic trials to ensure safety.

Only 0.9% of the Japanese public received their first vaccine shot as of Friday, compared with 2.5% in South Korea, and 48% in the United Kingdom.

Japan's top health experts have acknowledged that the Covid-19 pandemic has entered a fourth wave.

Japan has exhibited "poor performance" in containing virus transmission, along with limited testing capacity and a slow vaccination rollout, according to a commentary of health experts published in the British Medical Journal on Wednesday.

Tokyo's Olympics chief said on Friday that Japan was committed to holding a safe Games this summer, as a surge in Covid-19 cases prompted an expansion of contagion controls and with fresh calls for the Games to again be postponed or canceled.

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.